

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(Incorporated in the Cayman Islands as an exempted company with limited liability)

(Stock code: 1873)

VOLUNTARY ANNOUNCEMENT APPROVAL OF ENVIRONMENTAL IMPACT REPORT FOR LANGHUA PHARMACEUTICAL

This announcement is made by Viva Biotech Holdings (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The Company is pleased to announce that Zhejiang Langhua Pharmaceutical Co., Ltd. (浙江朗華製藥有限公司, “**Langhua Pharmaceutical**”), a wholly-owned subsidiary of the Company, has recently obtained a reply from the Taizhou Ecological Environment Bureau (台州市生態環境局) in relation to Langhua Pharmaceutical’s environmental impact report (the “**Reply**”) regarding the Company’s proposed production of certain peptides and advanced intermediates for other small-molecule drugs.

The Reply approved Langhua Pharmaceutical’s proposal to remodel three existing plants in Linhai Park of the Zhejiang Province Chemical Active Pharmaceutical Ingredient Base (浙江省化學原料藥基地臨海園區) for production of peptides and advanced intermediates for other small-molecule drugs in accordance with the terms and plans set forth in the environmental impact report.

Langhua Pharmaceutical intends to implement the production plans set forth in the environmental impact report and comply with the relevant requirements set forth in the Reply as well as relevant laws and regulations in managing the project, striving to commence production as soon as practicable.

The production plans are expected to benefit the Group in facilitating its business growth, increasing its production capabilities and capacities. The Company wishes to note that no forecast or prediction of the profit of the Group has been made in relation to such production plans.

Shareholders of the Company and potential investors should exercise caution when dealing in the securities of the Company.

By order of the Board
Viva Biotech Holdings
Mao Chen Cheney
Chairman and Chief Executive Officer

Hong Kong, January 29, 2026

As at the date of this announcement, the Board comprises three Executive Directors, namely, Mr. Mao Chen Cheney (Chairman), Mr. Wu Ying and Mr. Ren Delin; two Non-executive Directors, namely, Mr. Wu Yuting and Mr. Wang Stephen Hui; and three Independent Non-executive Directors, namely, Mr. Fu Lei, Ms. Li Xiangrong and Mr. Wang Haiguang.